Check 35,000+ stocks against 26 valuation models and 37 quality factors

Beijing Wandong Medical Technology Co Ltd (600055) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Beijing Wandong Medical Technology Co Ltd ¥2.43, price ¥10.58, upside -77.0%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? No
Good quality? No
Add to watchlist

Healthcare · CN · ISIN CNE000000PZ1

BW Thin data Sep 23, 2026

Beijing Wandong Medical Technology Co Ltd

600055 · SHG

Weakest SetupStrongly overvalued and low quality.

!Fair value ¥2.43 · Strongly overvalued (−77%)

!Quality 43/100

!Expensive Growth (revenue 5y +3.4 %/yr)

!Loss-making · -20.2% net margin (TTM)

!Low debt · negative free cash flow

!Trails peers (4/11)

!Narrow moat 20/100

!Evidence only low, so the estimate is less certain

!Weak on dividend: 22 out of 100

26 models, one by oneBear ¥1.18 to bull ¥3.82 Growth analysisrevenue history, year by year Quality 43/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Beijing Wandong Medical Technology Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range ¥10.00 – ¥34.38 · fair‑value band ¥1.18 – ¥3.82 · the ¥10.58 price screens above the ¥2.43 fair value. Dashed = 300-day average. As of Sep 23, 2026.

Follow Beijing Wandong Medical Technology Co in your weekly email

Every Wednesday you see whether Beijing Wandong Medical Technology Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Beijing Wandong Medical Technology Co.,Ltd. engages in the research, development, manufactures, sales, and after-sale services of digital imaging equipment in China. It operates through two segments Medical Equipment Sales Business; and Medical Services and Others. The company provides digital X radiography system (DR), including panorama DR; magnetic resonance imaging system (MRI) for clinical magnetic resonance imaging; X-ray computed tomography system (CT) for clinical X-ray; vascular interventional therapy system (DSA) for clinical examination and interventional treatment of cardiovascular, cerebrovascular, peripheral vascular, and other diseases; flat panel gastrointestinal diagnostic system; digital flat panel breast system; and mobile x-ray machine. The company was formerly known as China Resources Wandong Medical Equipment Co., Ltd. Beijing Wandong Medical Technology Co.,Ltd. company was founded in 1955 and is headquartered in Beijing, China.

Stock analysis

Beijing Wandong Medical Technology Co Ltd (600055) currently trades at ¥10.58, while our model-based Fair Value estimate is ¥2.43, implying the stock looks roughly 335.4% overvalued today.

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥4.25 per share, and 0 of the 3 models we run sit above the ¥10.58 price.

Bear case: the Dividend Discount group reads lowest at ¥1.55, and 3 of the 3 models stay below the price. Evidence for this calculation is low.

Scenario range: ¥1.18 (bear) to ¥3.82 (bull), the price of ¥10.58 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Beijing Wandong Medical Technology Co Ltd reported revenue of 1.3B CNY in FY2025 versus 1.2B CNY in FY2021, a compound +3.8%/yr. Reported net income was −228M CNY in FY2025.

Key figures

Market cap 8.4B CNY (≈ $1.2B) · P/S ratio 6.05 · EPS (TTM) ¥−0.4000 · Dividend yield 1.1% · Net margin −17.0% · Return on equity −5.9% · Return on assets (EBIT) 2.3% · Operating margin −4.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).

What moves the price

The share trades about 41% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −77%, 600055 screens richer than that median.

Fair Value models

Bear ¥1.18 Fair Value ¥2.43 Bull ¥3.82

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

Gordon GGM ¥1.01 ¥1.82 ¥2.51 68

DDM Multi-Stage ¥1.01 ¥1.55 ¥1.94 67

NCAV (Graham) ¥3.17 ¥4.25 ¥6.34 54

All 3 models by family

Dividend Discount

Gordon GGM ¥1.01 ¥1.82 ¥2.51 68

DDM Multi-Stage ¥1.01 ¥1.55 ¥1.94 67

Asset-Based

NCAV (Graham) ¥3.17 ¥4.25 ¥6.34 54

Open the full fair value analysis →

Notify me when 600055 reaches fair value

Put 600055 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 44 · Market factors (momentum, volatility) 35

Profitability 4

Margins and returns on capital today

Quality Growth 5

Are margins and returns improving?

Cashflow 14

Earnings quality: real cash, not paper profit

Fin. Strength 100

Balance sheet, leverage, solvency risk

Investment 85

Disciplined investing over empire-building

Low Volatility 84

Calm price path (market factor)

Momentum 20

Price trend over the last 3–12 months (market factor)

52W Momentum 3

Distance to the 52-week high (market factor)

Net Issuance 72

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 13/100

The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Revenue growth 1 year

−12.1%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+6.1%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+3.4%

Start year 2020 (pandemic). Over 10 years: +5.1% a year

Revenue growth 31 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+9.1%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

23.3% (2020) → −27.7% (2025)

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

600055 screens 335% overvalued. Compare with Abbott Laboratories, →

Compare Beijing Wandong Medical Technology Co Ltd with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 364 stocks

Beats the industry median on 3/9 measures

Overall it trails its industry peers.

Valuation

Quality Score 43 · Below median

Fair Value upside −77% · Bottom 25%

Profitability

Return on assets −5% · Below median

Net margin (TTM) −20% · Bottom 25%

Operating margin (TTM) −5% · Below median

Growth and dividend

Revenue growth 9% · Above median

Dividend yield (TTM) 1.1% · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.28× · Cheapest 25%

P/S (TTM) 0.90× · Cheaper than median

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 8

FUTURE (revenue growth)45 · sector 31

PAST (return on equity)0 · sector 8

HEALTH (low debt)100 · sector 97

DIVIDEND (yield)22 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Abbott Laboratories, ABT	$103.69	$74.79	−28%
Stryker Corporation SYK	$275.09	$302.60	+10%
Medtronic plc MDT	$90.77	$65.57	−28%
Boston Scientific Corporation BSX	$44.92	$49.41	+10%
Edwards Lifesciences Corporation EW	$88.78	$82.04	−8%
Siemens Healthineers AG SHL	€37.43	€35.22	−6%
DexCom, Inc DXCM	$89.53	$98.48	+10%
GE HealthCare Technologies Inc GEHC	$66.27	$69.62	+5%
Shenzhen Mindray Bio-Medical Electronics Co 300760	¥156.68	¥172.35	+10%
Koninklijke Philips N.V PHIA	€21.85	€15.32	−30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Beijing Wandong Medical Technology Co Ltd · Fair Value
¥2.43 −335%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/600055" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Beijing Wandong Medical Technology Co Ltd · Fair Value</span><br><b style="font-size:20px">¥2.43</b> <span style="color:#e0816f;font-weight:700;font-size:14px">−335%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Beijing Wandong Medical Technology Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/600055

Frequently asked questions

Is Beijing Wandong Medical Technology Co Ltd (600055) overvalued or undervalued?

As of Sep 23, 2026, our model estimates a fair value of ¥2.43 versus a price of ¥10.58, about −77% upside (overvalued).

What is the fair value of 600055?

Our model-based fair value for Beijing Wandong Medical Technology Co Ltd is ¥2.43 (as of Sep 23, 2026), built from audited fundamentals. The current price: ¥10.58.

What is the quality score of 600055?

Beijing Wandong Medical Technology Co Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Beijing Wandong Medical Technology Co Ltd (600055)?

Our model-based price target is the fair value of ¥2.43 (as of Sep 23, 2026) from 3 valuation models. Cautious scenario ¥1.18, optimistic scenario ¥3.82. It is a calculation from audited fundamentals, not an analyst target.

What is the Beijing Wandong Medical Technology Co Ltd stock forecast for 2026?

Our models put fair value at ¥2.43, about −77% upside versus a price of ¥10.58 (overvalued). Cautious scenario ¥1.18, optimistic scenario ¥3.82. The calculation is refreshed regularly with new filings.

What is the revenue of Beijing Wandong Medical Technology Co Ltd (600055)?

Beijing Wandong Medical Technology Co Ltd reported trailing-twelve-month revenue of about 1.4B CNY (latest available figure, as of Sep 23, 2026).

Does Beijing Wandong Medical Technology Co Ltd pay a dividend?

Beijing Wandong Medical Technology Co Ltd currently shows a dividend yield of about 1.09% relative to its recent price (as of Sep 23, 2026).

What is the intrinsic value of Beijing Wandong Medical Technology Co Ltd (600055)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Beijing Wandong Medical Technology Co Ltd it is ¥2.43 per share (as of Sep 23, 2026), against a price of ¥10.58. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).

Is Beijing Wandong Medical Technology Co Ltd stock overvalued or undervalued in 2026?

As of Sep 23, 2026, 600055 trades above its calculated fair value: price ¥10.58, fair value ¥2.43, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 600055?

No. The price is what the market pays today (¥10.58); the fair value is what the company's own numbers justify (¥2.43). For Beijing Wandong Medical Technology Co Ltd the two are ¥8.15 per share apart. That gap is exactly why we show both numbers side by side.

How much is Beijing Wandong Medical Technology Co Ltd worth?

The market values Beijing Wandong Medical Technology Co Ltd at about 8.4B CNY (market capitalisation, as of Sep 23, 2026). Per share that is ¥10.58; our models calculate a fair value of ¥2.43 per share.

What do the bullish and bearish scenarios say about 600055?

Our models span a range for Beijing Wandong Medical Technology Co Ltd: cautious scenario ¥1.18, base ¥2.43, optimistic ¥3.82 per share (as of Sep 23, 2026, price ¥10.58). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Beijing Wandong Medical Technology Co Ltd (600055)?

Balance-sheet figures for Beijing Wandong Medical Technology Co Ltd (as of Sep 23, 2026): return on equity −5.9%. They feed the Quality Score of 43/100, which measures business quality independently of the share price.

How far is 600055 from its 52-week high?

Beijing Wandong Medical Technology Co Ltd trades at ¥10.58, about 41% below its 52-week high of ¥17.92 and 6% above the low of ¥10.00 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of ¥2.43 is for.

Which stocks are comparable to Beijing Wandong Medical Technology Co Ltd?

From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Beijing Wandong Medical Technology Co Ltd stock attractive at the current price?

The data as of Sep 23, 2026: price ¥10.58, calculated fair value ¥2.43 (−77%), Quality Score 43/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 600055 calculated?

We run Beijing Wandong Medical Technology Co Ltd through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥2.43, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. Beijing Wandong Medical Technology Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Beijing Wandong Medical Technology Co Ltd (600055)?

The closing price on Sep 23, 2026 was ¥10.58. Our model-based fair value is ¥2.43, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Beijing Wandong Medical Technology Co Ltd right now?

The price sits above even our optimistic bull case (¥3.82). The favourable scenario is already priced in. Weak quality (43/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (¥1.18 to ¥3.82). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Where does the earnings growth of Beijing Wandong Medical Technology Co Ltd (600055) come from?

Earnings per share at Beijing Wandong Medical Technology Co Ltd grew +10.7 % a year from 2015 to 2025. Broken into its drivers: revenue per share +2.7 %, EBIT margin +17.3 %, tax rate +1.0 %, residual (interest, one-offs) −9.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Beijing Wandong Medical Technology Co Ltd

How large is the market capitalisation of Beijing Wandong Medical Technology Co Ltd (600055)?

The market capitalisation of Beijing Wandong Medical Technology Co Ltd is 8.4B CNY (≈ $1.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Beijing Wandong Medical Technology Co Ltd (600055)?

The price-to-sales ratio of Beijing Wandong Medical Technology Co Ltd is 6.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Beijing Wandong Medical Technology Co Ltd (600055)?

Earnings per share at Beijing Wandong Medical Technology Co Ltd are ¥−0.4000. Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Beijing Wandong Medical Technology Co Ltd (600055)?

The dividend yield of Beijing Wandong Medical Technology Co Ltd is 1.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Beijing Wandong Medical Technology Co Ltd (600055)?

The net margin of Beijing Wandong Medical Technology Co Ltd is −17.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Beijing Wandong Medical Technology Co Ltd (600055)?

The return on equity (ROE) of Beijing Wandong Medical Technology Co Ltd is −5.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Beijing Wandong Medical Technology Co Ltd (600055)?

On an EBIT basis the return on assets of Beijing Wandong Medical Technology Co Ltd is 2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Beijing Wandong Medical Technology Co Ltd (600055)?

The operating margin of Beijing Wandong Medical Technology Co Ltd is −4.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Beijing Wandong Medical Technology Co Ltd (600055)?

Revenue at Beijing Wandong Medical Technology Co Ltd is growing +8.9% versus a year earlier (3y avg +6.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Beijing Wandong Medical Technology Co Ltd (600055)?

Earnings per share at Beijing Wandong Medical Technology Co Ltd are growing −69.0% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Beijing Wandong Medical Technology Co Ltd (600055) generate?

The free cash flow of Beijing Wandong Medical Technology Co Ltd is −351M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Beijing Wandong Medical Technology Co Ltd (600055) hold?

Beijing Wandong Medical Technology Co Ltd holds more cash than debt, 2.8B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Beijing Wandong Medical Technology Co Ltd in the live analysis

One click puts Beijing Wandong Medical Technology Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.